A clinician-level review of AndroGel (testosterone gel 1%/1.62%) and kidney outcomes: what the T-Trials, pharmacokinetic data, and current guidelines say about renal protection and renal risk in hypogonadal men.
A deep dive into how AndroGel (testosterone gel 1% and 1.62%) affects libido, erectile function, and sexual activity in hypogonadal men, with primary-trial data, dosing details, and clinical guidance.
How AndroGel (testosterone gel 1% and 1.62%) affects sleep quality, sleep architecture, and sleep-disordered breathing in men with hypogonadism, and how to decide whether pre-treatment sleep apnea screening is needed.
A physician-level review of AOD-9604 (HGH fragment 176-191) pharmacogenomics, covering GHR and GHSR variant effects, beta-3 adrenergic receptor polymorphisms, metabolic enzyme influences, and how genetic testing may predict individual response.
A clinician-level review of how AOD-9604 (HGH fragment 176-191) affects appetite and food cravings, covering mechanism, clinical data, dosing, and what to expect during treatment.
A clinician-level review of AOD-9604 (HGH fragment 176-191) and cognitive function, covering mechanism, available human and animal data, safety, and how it compares with other growth-hormone-axis peptides.
A deep-dive into AOD-9604 (HGH fragment 176-191) and its reported effects on hair and skin, including lipolysis mechanisms, IGF-1 signaling, and what current evidence does and does not support.
A clinician-level review of AOD-9604 (HGH fragment 176-191) and kidney safety, covering available pharmacology, preclinical data, renal-risk signals, and what prescribers should monitor.
A guide to how Armour Thyroid (natural desiccated thyroid) affects hair loss, hair regrowth, skin texture, and dryness, with primary-literature citations, real doses, and clinical decision frameworks.
FDA-approved oxandrolone dosing is 2.5-20mg/day. Covers liver enzyme changes, lipid effects, testosterone suppression, and monitoring needs from clinical data.
SARMs are not FDA-approved, banned by WADA, and illegal to sell as dietary supplements in the US. This guide covers the law, muscle-building evidence, PCT requirements, drug testing, and safer alternatives.
A guide to body recomposition across populations: competitive athletes, recreational lifters, post-bariatric patients, older adults, and women. Includes specific protocols, trial data, and dosing frameworks.
Understand fat mass, lean tissue, DXA and impedance measurements, plus research on strength training, protein, GLP-1 treatment, sleep, and body recomposition.
A guide to diagnosing and fixing a bulking plateau, covering progressive overload failures, protein targets, hormonal blockers, visceral fat accumulation, sarcopenia risk, and GLP-1 recomp strategies.
A detailed clinical comparison of clenbuterol and cardarine (GW501516) for fat loss and body composition, covering mechanisms, side effects, legal status, and safer alternatives. prepared by the HealthRX.com Editorial Team.
SARMs do produce measurable lean-mass gains in clinical trials, but the effect sizes are modest, the legal status is complicated, and the safety data are thin. Here is what the research actually says before you consider using one.
Creatine monohydrate is the most evidence-backed legal supplement for muscle and strength, but how far does it actually take you without training, diet, or other interventions? A breakdown of what creatine does and doesn't do, how it compares to SARMs and anavar, and when a medical provider should be involved.
Evidence-based guide to LGD-4033 cycle length, dosing protocols, testosterone suppression data, and PCT requirements. prepared by the HealthRX.com Editorial Team.
Loose skin comes from damaged collagen and elastin, not just fat loss. See the weight threshold, non-surgical options, and when surgery is the only fix.
A guide to body recomposition for older adults, covering protein targets, resistance training, GLP-1 medications, hormones, and post-bariatric considerations.
Stuck at the same weight and body composition for weeks? Learn the clinical reasons behind a recomp plateau, covering stubborn visceral fat, sarcopenia, and bulking stalls, plus evidence-based strategies to restart progress.
A guide to sarcopenia covering diagnostic criteria, muscle loss rates, resistance training protocols, protein targets, and GLP-1 considerations for lean mass preservation.
SARMs reports show cholestatic and mixed liver injury from ostarine, LGD-4033, and RAD-140, with recovery typically taking 4 to 16 weeks after stopping.
Research on women shows simultaneous muscle gain and fat loss is real, needing 1.6-2.4g/kg protein and 2-4 weekly resistance sessions to work.
A clinician-level review of BPC-157 pentadecapeptide and cancer risk. Covers angiogenesis data, tumor-promotion signals, FDA regulatory status, and what patients starting compounded BPC-157 need to know before their first injection.
A clinician-level review of BPC-157 pentadecapeptide and its reported effects on hair growth and skin healing, covering mechanisms, animal trial data, compounding regulations, and what patients should realistically expect.
A analysis of BPC-157 pentadecapeptide and its effects on liver function, covering animal data, proposed mechanisms, safety signals, and where compounded BPC-157 stands clinically.
A clinician-level review of BPC-157 pentadecapeptide for muscle preservation: mechanisms, dosing protocols, safety data, and where the evidence stands in 2025.
A clinician-level review of BPC-157 pentadecapeptide and the kidneys: preclinical renal protection data, proposed mechanisms, toxicology signals, and what compounding patients need to know before starting.
A clinical deep-dive into how BPC-157 pentadecapeptide may affect sexual function, covering the proposed mechanisms, animal-model data, the absence of human RCTs, dosing considerations, and what compounding regulations mean for patients today.
An independent clinical assessment of Alloy Women's menopause HRT platform: prescribing model, compounded hormone safety, regulatory standing, cost, and how it compares to alternatives.
An independent clinical review of Alloy's menopause HRT platform, covering prescribing scope, formulary limits, monitoring gaps, and how it compares to alternatives.
An evidence-based breakdown of who benefits most from Amble's cash telehealth GLP-1 program, including clinical eligibility criteria, realistic weight-loss expectations, and how it compares to alternatives.
An independent, evidence-based synthesis of Belmar Pharmacy compounded BHRT outcomes, cost, legitimacy, and how it compares to alternatives, prepared by the HealthRX.com Editorial Team.
An independent clinical review of Brightside Health's depression and anxiety telehealth service, covering prescribing scope, evidence gaps, cost, and when patients need a higher level of care.
An evidence-based assessment of Care/of's safety record, regulatory standing, third-party testing practices, and how it compares to alternatives. prepared by the HealthRX.com Editorial Team.
Done ADHD costs $199 the first month, then $79-$99 monthly, plus $30-$300+ for medication. Total annual cost can top $1,500. See the full breakdown.
An independent clinical review of Done, the ADHD telehealth platform. We examine prescribing practices, clinical gaps, regulatory risks, cost, and how Done compares to alternatives, with primary-source citations throughout.
An independent review of Help Pharmacy's compounding model, GLP-1 and HRT products, regulatory standing, pricing, and how it compares with alternatives. prepared by the HealthRX.com Editorial Team.
A detailed breakdown of Found's membership fees, GLP-1 drug costs, and total out-of-pocket expenses compared with alternatives. prepared by the HealthRX.com Editorial Team.
A breakdown of how Function Health works, what it prescribes, how much it costs, and how it compares to alternatives, with an evidence-boundary review of the lab panels it uses.
An independent, evidence-based analysis of Happy Head's compounded hair loss treatments, real customer outcomes, costs, and how the brand compares to alternatives. Reviewed by HealthRX.com physicians.
Bupa doesn't cover Juniper's GLP-1 program; monthly fees run AU$99-599 depending on medication tier, plus dietitian coaching, with no lock-in contract.
An independent clinical review of Juniper's women's GLP-1 and nutrition telehealth model, examining evidence gaps, prescribing limitations, cost, and how it compares to alternatives.
An evidence-based breakdown of the Juniper ideal patient profile, covering eligibility criteria, what the program prescribes, how it compares to alternatives, and what real clinical outcomes look like for women pursuing GLP-1-assisted weight management.
An independent clinical analysis of Levels Health's CGM-driven metabolic platform. What the glucose data shows, what it misses, and how it compares to alternatives for people seeking real metabolic care.
An evidence-based assessment of Life Extension's safety record, regulatory posture, third-party testing practices, and how its supplement and Rx offerings compare against available clinical evidence.
An evidence-based comparison of Marek Health and its top alternatives for TRT, peptides, HRT, and lab optimization. prepared by the HealthRX.com Editorial Team.
A clinical breakdown of Mochi Health alternatives for GLP-1 weight loss, TRT, HRT, and metabolic care. Compare cost, prescribing model, and outcomes so you can choose the right telehealth platform.
A clinical breakdown of Mochi Health's intake and prescription process for GLP-1 weight loss therapy, including costs, legitimacy, what drugs are prescribed, and how it stacks up against alternatives.
An evidence-based critical analysis of Mochi Health's GLP-1 weight-loss telehealth model, including clinical gaps, cost structure, prescribing limits, and how it compares to alternatives.
An independent clinical review of Momentous performance supplements, covering creatine evidence, protein quality, third-party testing gaps, pricing, and how the brand compares to pharmaceutical-grade alternatives.
An evidence-based look at the ideal user profile for Momentous performance supplements, including creatine, protein, and sleep formulas. prepared by the HealthRX.com Editorial Team.
An independent, evidence-based assessment of Olipop's safety profile, ingredient regulation, gut-health claims, and how it compares to alternatives. prepared by the HealthRX.com Editorial Team.
A breakdown of the best PlushCare alternatives for GLP-1 weight loss, primary care, mental health, and more, with real costs, prescribing data, and head-to-head comparisons.
Seed's DS-01 has only one published RCT on the full formula. See what the research actually shows on strains, dosing, and price before you subscribe.
An evidence-based look at Shapiro MD's direct-to-consumer hair loss model, what it prescribes, how it compares to alternatives, and whether the clinical evidence supports its claims.
A critical, evidence-based review of Strut Health's compounding telehealth model, what it prescribes for hair loss, skin, and sexual health, how it compares to alternatives, and what real costs look like.
An evidence-based review of Superpower's safety posture, regulatory standing, prescribing practices for GLP-1s and peptides, and how it compares to competing telehealth platforms. Written and prepared by the HealthRX.com Editorial Team.
An independent clinical analysis of Truepill's B2B pharmacy infrastructure model and the best alternatives for GLP-1, TRT, HRT, peptide, and direct-to-patient telehealth use cases in 2025.